Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ciclosporin ophthalmic - Santen

Drug Profile

Ciclosporin ophthalmic - Santen

Alternative Names: Cyclosporin modified ophthalmic - Santen; Cyclosporin ophthalmic - Santen; DE 076; PAPILOCK Mini ophthalmic solution 0.1%; Sanciclo

Latest Information Update: 10 Feb 2006

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
  • Mechanism of Action Cytokine inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Seasonal allergic rhinitis

Highest Development Phases

  • Marketed Seasonal allergic rhinitis

Most Recent Events

  • 23 Jan 2006 First global launch of ciclosporin ophthalmic
  • 23 Jan 2006 Launched for Seasonal allergic rhinitis in Japan (Ophthalmic)
  • 11 Oct 2005 Registered for Seasonal allergic rhinitis in Japan (Ophthalmic)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top